Veru (NASDAQ:VERU) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of Veru (NASDAQ:VERU) from a sell rating to a strong sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

VERU has been the topic of several other research reports. Oppenheimer reissued an “outperform” rating on shares of Veru in a report on Wednesday, October 14th. Westpark Capital assumed coverage on Veru in a research note on Tuesday, October 6th. They set a “buy” rating for the company. Finally, Weiss Ratings lowered Veru from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 16th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.50.

Veru Stock Performance

VERU stock opened at $2.16 on Friday. Veru has a 52 week low of $2.05 and a 52 week high of $7.33. The firm’s 50-day moving average is $2.45 and its two-hundred day moving average is $2.50.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. Equities analysts anticipate that Veru will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Veru

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FNY Investment Advisers LLC bought a new position in shares of Veru during the 2nd quarter valued at about $328,000. Renaissance Technologies LLC acquired a new position in shares of Veru in the 1st quarter worth approximately $153,000. Finally, Royal Bank of Canada grew its stake in shares of Veru by 69.3% in the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after purchasing an additional 5,008 shares during the last quarter. 47.16% of the stock is owned by institutional investors and hedge funds.

About Veru

Veru Inc is a biopharmaceutical company focused on developing medicines for oncology and metabolic diseases. The company’s pipeline includes therapies intended to address cancer-related muscle wasting, obesity, and other conditions associated with the loss of lean body mass and physical function.

Veru’s principal investigational product is enobosarm, an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function in patients with cancer-related wasting and obesity.